They received seven days therapy with moxifloxcin 400 mg once a day, rabeprazole 10 mg twice a day and amoxicillin 1,000 mg twice a day. At least 4 weeks after the completion
of therapy, the patients conducted the 13C-UBT or CLO test. Results: Twenty patients with 10 males were recruited. The mean age of the patients was 50.2 years, ranging from 29 to 67 years. Five patients defaulted follow up. One patient dropped out this treatment due to mild urticaria. The eradication rate (Per Protocol analysis) was 85.7% (12/14). Conclusion: In consider with little adverse effect and high eradication rates, the moxifloxacin-based triple therapy may be a safe and effective second-line treatment option for H. pylori eradication. Extended treatment duration with this regimen may enhance the eradication rate. Key CH5424802 research buy Word(s): 1. H. pylori; 2. moxifloxacin; 3. eradication Presenting Author: ERNEST HAN FAI LI Additional Authors: Na Corresponding Author: ERNEST HAN FAI LI Affiliations: Na Objective: Eradication see more rate for Helicobacter pylori infection with clarithromycin-based triple therapy has fallen worldwide. The primary purpose of this study is to find out the current eradication success rate in Hong Kong. Secondary objectives
are the primary resistance rate of Helicobacter pylori to antibiotics commonly used in eradication regimens; risk factors for treatment failure; and risk factors for antibiotics resistance. Methods: One hundred and forty-seven treatment-naïve patients
were identified by 13C-urea breath test from May 2011 to September 2012. Biopsy samples were taken during esophagogastroduodenoscopy for histological analysis, culture and antibiotics susceptibility testing. Enrolled patients were then treated with lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 g b.d. for 7 days. Eradication success was evaluated by 13C-urea breath test at least 4 weeks after treatment. Results: Helicobacter pylori eradication was achieved in 82.9% and 85.2% of patients by intention-to-treat and per-protocol analysis respectively. Clarithromycin-resistance was detected in 13.1% of subjects 上海皓元医药股份有限公司 and correlated to an eradication rate of 6.3% (p < 0.001). Levofloxacin-resistance was detected in 15.6% of subjects and type 2 diabetes mellitus is a risk factor for levofloxacin-resistance (OR 4.3, p = 0.019). Metronidazole-resistance rate was 59.0%. No amoxicillin- or tetracycline- resistances were detected. Conclusion: The 7-day clarithromycin-based therapy is still a valid empirical first-line treatment for Helicobacter pylori infection in Hong Kong. However, its effectiveness is decreasing owing to the increased prevalence of primary resistance to clarithromycin. Alternative effective regimen is yet to be determined as bismuth is no longer available in Hong Kong, and the resistant rate to levofloxacin is considerable. Key Word(s): 1. Helicobacter pylori; 2. antibiotics resistance; 3.